Prelude Therapeutics Director Makes Significant Stock Purchase

A director at Prelude Therapeutics has acquired $12.5 million worth of the company's stock. This substantial insider buying is often viewed as a strong indicator of confidence in the firm's future prospects. Such transactions can influence market perceptions and investor sentiment within the biotechnology sector.